Cell entry of hepatitis C virus

Virology

Volumn 348, Issue 1, 2006, Pages 1-12

  Bartosch, Birke ^a,b,c   Cosset, François Loïc ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ DE LYON   (France)

^c University Lyon i   (France)

Author keywords

Cell entry; Glycoprotein; Hepatitis C virus; Lipoprotein; Receptor

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; CD81 ANTIGEN; CELL RECEPTOR; CHIMERIC PROTEIN; GLYCOSAMINOGLYCAN; HEPATITIS C VACCINE; HIGH DENSITY LIPOPROTEIN; LECTIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; NEUTRALIZING ANTIBODY; NUCLEOCAPSID PROTEIN; SCAVENGER RECEPTOR BI; STRUCTURAL PROTEIN; TETRASPANIN; VIRUS GLYCOPROTEIN; VIRUS PROTEIN;

AMINO TERMINAL SEQUENCE; CARBOXY TERMINAL SEQUENCE; CELL ADHESION; CELL FUSION; COMPARATIVE STUDY; DENGUE VIRUS; ENDOCYTOSIS; EXPERIMENTAL MOUSE; FLAVIVIRUS; HEPATITIS C; HEPATITIS C VIRUS; HEPATOMA CELL; HUMAN; IMMUNOPATHOGENESIS; IN VITRO STUDY; INSECT CELL; LIVER CELL; MAMMAL CELL; MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; RECEPTOR AFFINITY; REVIEW; SPECIES COMPARISON; SPECIES DIFFERENCE; STRUCTURE ACTIVITY RELATION; SUPERNATANT; VIRUS ADSORPTION; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS INFECTIVITY; VIRUS MORPHOLOGY; VIRUS NUCLEOCAPSID; VIRUS PARTICLE; VIRUS PATHOGENESIS; YELLOW FEVER FLAVIVIRUS;

HEPACIVIRUS; VIRAL ENVELOPE PROTEINS; VIRUS REPLICATION;

DENGUE VIRUS; FLAVIVIRIDAE; FLAVIVIRUS; HEPACIVIRUS; HEPATITIS C VIRUS; INSECTA; MAMMALIA; RNA VIRUSES; YELLOW FEVER VIRUS;

EID: 33646024277     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2005.12.027     Document Type: Review

References (123)

1. Agnello V., and Abel G. Localization of hepatitis C virus in cutaneous vasculitic lesions in patients with type II cryoglobulinemia. Arthritis Rheum. 40 11 (1997) 2007-2015
2. Agnello V., Abel G., Elfahal M., Knight G.B., and Zhang Q.X. Hepatitis C virus and other Flaviviridae viruses enter cells via low density lipoprotein receptor. Proc. Natl. Acad. Sci. U.S.A. 96 22 (1999) 12766-12771
3. Allison S.L., Schalich J., Stiasny K., Mandl C.W., Kunz C., and Heinz F.X. Oligomeric rearrangement of tick-borne encephalitis virus envelope proteins induced by an acidic pH. J. Virol. 69 2 (1995) 695-700
4. Allison S.L., Stiasny K., Stadler K., Mandl C.W., and Heinz F.X. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J. Virol. 73 7 (1999) 5605-5612
5. Andre P., Komurian-Pradel F., Deforges S., Perret M., Berland J.L., Sodoyer M., Pol S., Brechot C., Paranhos-Baccala G., and Lotteau V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 76 14 (2002) 6919-6928
6. Barth H., Schafer C., Adah M.I., Zhang F., Linhardt R.J., Toyoda H., Kinoshita-Toyoda A., Toida T., Van Kuppevelt T.H., Depla E., Von Weizsacker F., Blum H.E., and Baumert T.F. Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J. Biol. Chem. 278 42 (2003) 41003-41012
7. Barth H., Cerino R., Arcuri M., Hoffmann M., Schurmann P., Adah M.I., Gissler B., Zhao X., Ghisetti V., Lavezzo B., Blum H.E., von Weizsacker F., Vitelli A., Scarselli E., and Baumert T.F. Scavenger receptor class B type I and hepatitis C virus infection of primary tupaia hepatocytes. J. Virol. 79 9 (2005) 5774-5785
8. Bartosch B., and Cosset F.L. Strategies for retargeted gene delivery using vectors derived from lentiviruses. Curr. Gene Ther. 4 4 (2004) 427-443
9. Bartosch B., Bukh J., Meunier J.C., Granier C., Engle R.E., Blackwelder W.C., Emerson S.U., Cosset F.L., and Purcell R.H. In vitro assay for neutralizing antibody to hepatitis C virus: evidence for broadly conserved neutralization epitopes. Proc. Natl. Acad. Sci. U.S.A. 100 24 (2003) 14199-14204
10. Bartosch B., Dubuisson J., and Cosset F.L. Infectious hepatitis C virus pseudo-particles containing functional E1-E2 envelope protein complexes. J. Exp. Med. 197 5 (2003) 633-642
11. Bartosch B., Vitelli A., Granier C., Goujon C., Dubuisson J., Pascale S., Scarselli E., Cortese R., Nicosia A., and Cosset F.L. Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor. J. Biol. Chem. 278 43 (2003) 41624-41630
12. Bartosch B., Verney G., Dreux M., Donot P., Morice Y., Penin F., Pawlotsky J.M., Lavillette D., and Cosset F.L. An interplay between hypervariable region 1 of the hepatitis C virus E2 glycoprotein, the scavenger receptor BI, and high-density lipoprotein promotes both enhancement of infection and protection against neutralizing antibodies. J. Virol. 79 13 (2005) 8217-8229
13. Baumert T.F., Ito S., Wong D.T., and Liang T.J. Hepatitis C virus structural proteins assemble into viruslike particles in insect cells. J. Virol. 72 5 (1998) 3827-3836
14. Baumert T.F., Vergalla J., Satoi J., Thomson M., Lechmann M., Herion D., Greenberg H.B., Ito S., and Liang T.J. Hepatitis C virus-like particles synthesized in insect cells as a potential vaccine candidate. Gastroenterology 117 6 (1999) 1397-1407
15. Beglova N., and Blacklow S.C. The LDL receptor: how acid pulls the trigger. Trends Biochem. Sci. 30 6 (2005) 309-317
16. Blanchard E., Brand D., Trassard S., Goudeau A., and Roingeard P. Hepatitis C virus-like particle morphogenesis. J. Virol. 76 8 (2002) 4073-4079
17. Blanchard E., Hourioux C., Brand D., Ait-Goughoulte M., Moreau A., Trassard S., Sizaret P.Y., Dubois F., and Roingeard P. Hepatitis C virus-like particle budding: role of the core protein and importance of its Asp111. J. Virol. 77 18 (2003) 10131-10138
18. Bressanelli S., Stiasny K., Allison S.L., Stura E.A., Duquerroy S., Lescar J., Heinz F.X., and Rey F.A. Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 23 4 (2004) 728-738
19. Buonocore L., Blight K.J., Rice C.M., and Rose J.K. Characterization of vesicular stomatitis virus recombinants that express and incorporate high levels of hepatitis C virus glycoproteins. J. Virol. 76 14 (2002) 6865-6872
20. Cambi A., Koopman M., and Figdor C.G. How C-type lectins detect pathogens. Cell. Microbiol. 7 4 (2005) 481-488
21. Chen Y., Maguire T., Hileman R.E., Fromm J.R., Esko J.D., Linhardt R.J., and Marks R.M. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat. Med. 3 8 (1997) 866-871
22. Clark K.L., Oelke A., Johnson M.E., Eilert K.D., Simpson P.C., and Todd S.C. CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner. J. Biol. Chem. 279 19 (2004) 19401-19406
23. Clayton R.F., Owsianka A., Aitken J., Graham S., Bhella D., and Patel A.H. Analysis of antigenicity and topology of E2 glycoprotein present on recombinant hepatitis C virus-like particles. J. Virol. 76 15 (2002) 7672-7682
24. Cocquerel L., Meunier J.C., Pillez A., Wychowski C., and Dubuisson J. A retention signal necessary and sufficient for endoplasmic reticulum localization maps to the transmembrane domain of hepatitis C virus glycoprotein E2. J. Virol. 72 3 (1998) 2183-2191
25. Cocquerel L., Duvet S., Meunier J.C., Pillez A., Cacan R., Wychowski C., and Dubuisson J. The transmembrane domain of hepatitis C virus glycoprotein E1 is a signal for static retention in the endoplasmic reticulum. J. Virol. 73 4 (1999) 2641-2649
26. Cocquerel L., Wychowski C., Minner F., Penin F., and Dubuisson J. Charged residues in the transmembrane domains of hepatitis C virus glycoproteins play a major role in the processing, subcellular localization, and assembly of these envelope proteins. J. Virol. 74 8 (2000) 3623-3633
27. Connelly M.A., and Williams D.L. SR-BI and cholesterol uptake into steroidogenic cells. Trends Endocrinol. Metab. 14 10 (2003) 467-472
28. Cormier E.G., Durso R.J., Tsamis F., Boussemart L., Manix C., Olson W.C., Gardner J.P., and Dragic T. L-SIGN (CD209L) and DC-SIGN (CD209) mediate transinfection of liver cells by hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 101 39 (2004) 14067-14072
29. Cormier E.G., Tsamis F., Kajumo F., Durso R.J., Gardner J.P., and Dragic T. CD81 is an entry coreceptor for hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 101 19 (2004) 7270-7274
30. Cribier B., Schmitt C., Kirn A., and Stoll-Keller F. Inhibition of hepatitis C virus adsorption to peripheral blood mononuclear cells by dextran sulfate. Arch. Virol. 143 2 (1998) 375-379
31. Deforges S., Evlashev A., Perret M., Sodoyer M., Pouzol S., Scoazec J.Y., Bonnaud B., Diaz O., Paranhos-Baccala G., Lotteau V., and Andre P. Expression of hepatitis C virus proteins in epithelial intestinal cells in vivo. J. Gen. Virol. 85 Pt 9 (2004) 2515-2523
32. Drummer H.E., and Poumbourios P. Hepatitis C virus glycoprotein E2 contains a membrane-proximal heptad repeat sequence that is essential for E1E2 glycoprotein heterodimerization and viral entry. J. Biol. Chem. 279 29 (2004) 30066-30072
33. Drummer H.E., Maerz A., and Poumbourios P. Cell surface expression of functional hepatitis C virus E1 and E2 glycoproteins. FEBS Lett. 546 2-3 (2003) 385-390
34. Drummer H.E., Wilson K.A., and Poumbourios P. Determinants of CD81 dimerization and interaction with hepatitis C virus glycoprotein E2. Biochem. Biophys. Res. Commun. 328 1 (2005) 251-257
35. Dubuisson J. Folding, assembly and subcellular localization of hepatitis C virus glycoproteins. Curr. Top. Microbiol. Immunol. 242 (2000) 135-148
36. Dubuisson J., Duvet S., Meunier J.C., Op De Beeck A., Cacan R., Wychowski C., and Cocquerel L. Glycosylation of the hepatitis C virus envelope protein E1 is dependent on the presence of a downstream sequence on the viral polyprotein. J. Biol. Chem. 275 39 (2000) 30605-30609
37. Farci P., Shimoda A., Coiana A., Diaz G., Peddis G., Melpolder J.C., Strazzera A., Chien D.Y., Munoz S.J., Balestrieri A., Purcell R.H., and Alter H.J. The outcome of acute hepatitis C predicted by the evolution of the viral quasispecies. Science 288 5464 (2000) 339-344
38. Ferlenghi I., Clarke M., Ruttan T., Allison S.L., Schalich J., Heinz F.X., Harrison S.C., Rey F.A., and Fuller S.D. Molecular organization of a recombinant subviral particle from tick-borne encephalitis virus. Mol. Cell 7 3 (2001) 593-602
39. Flint M., Maidens C., Loomis-Price L.D., Shotton C., Dubuisson J., Monk P., Higginbottom A., Levy S., and McKeating J.A. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 73 8 (1999) 6235-6244
40. Flint M., Thomas J.M., Maidens C.M., Shotton C., Levy S., Barclay W.S., and McKeating J.A. Functional analysis of cell surface-expressed hepatitis C virus E2 glycoprotein. J. Virol. 73 8 (1999) 6782-6790
41. Flint M., Logvinoff C., Rice C.M., and McKeating J.A. Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J. Virol. 78 13 (2004) 6875-6882
42. Fournier C., Sureau C., Coste J., Ducos J., Pageaux G., Larrey D., Domergue J., and Maurel P. In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus. J. Gen. Virol. 79 Pt 10 (1998) 2367-2374
43. Fust G. Enhancing antibodies in HIV infection. Parasitology 115 (1997) S127-S140 (Suppl)
44. Gardner J.P., Durso R.J., Arrigale R.R., Donovan G.P., Maddon P.J., Dragic T., and Olson W.C. L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 100 8 (2003) 4498-4503
45. Garry R.F., and Dash S. Proteomics computational analyses suggest that hepatitis C virus E1 and pestivirus E2 envelope glycoproteins are truncated class II fusion proteins. Virology 307 2 (2003) 255-265
46. Garson J.A., Lubach D., Passas J., Whitby K., and Grant P.R. Suramin blocks hepatitis C binding to human hepatoma cells in vitro. J. Med. Virol. 57 3 (1999) 238-242
47. Germi R., Crance J.M., Garin D., Guimet J., Lortat-Jacob H., Ruigrok R.W., Zarski J.P., and Drouet E. Cellular glycosaminoglycans and low density lipoprotein receptor are involved in hepatitis C virus adsorption. J. Med. Virol. 68 2 (2002) 206-215
48. Goffard A., Callens N., Bartosch B., Wychowski C., Cosset F.L., Montpellier C., and Dubuisson J. Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins. J. Virol. 79 13 (2005) 8400-8409
49. Halstead S.B. Neutralization and antibody-dependent enhancement of dengue viruses. Adv. Virus Res. 60 (2003) 421-467
50. Hemler M.E. Tetraspanin proteins mediate cellular penetration, invasion, and fusion events and define a novel type of membrane microdomain. Annu. Rev. Cell Dev. Biol. 19 (2003) 397-422
51. Heo T.H., Chang J.H., Lee J.W., Foung S.K., Dubuisson J., and Kang C.Y. Incomplete humoral immunity against hepatitis C virus is linked with distinct recognition of putative multiple receptors by E2 envelope glycoprotein. J. Immunol. 173 1 (2004) 446-455
52. Higginbottom A., Quinn E.R., Kuo C.C., Flint M., Wilson L.H., Bianchi E., Nicosia A., Monk P.N., McKeating J.A., and Levy S. Identification of amino acid residues in CD81 critical for interaction with hepatitis C virus envelope glycoprotein E2. J. Virol. 74 8 (2000) 3642-3649
53. Hijikata M., Shimizu Y.K., Kato H., Iwamoto A., Shih J.W., Alter H.J., Purcell R.H., and Yoshikura H. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J. Virol. 67 4 (1993) 1953-1958
54. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., and McKeating J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U.S.A. 100 12 (2003) 7271-7276
55. Kanto T., Hayashi N., Takehara T., Hagiwara H., Mita E., Naito M., Kasahara A., Fusamoto H., and Kamada T. Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation. Hepatology 19 2 (1994) 296-302
56. Kato T., Furusaka A., Miyamoto M., Date T., Yasui K., Hiramoto J., Nagayama K., Tanaka T., and Wakita T. Sequence analysis of hepatitis C virus isolated from a fulminant hepatitis patient. J. Med. Virol. 64 3 (2001) 334-339
57. Keck Z.Y., Op De Beeck A., Hadlock K.G., Xia J., Li T.K., Dubuisson J., and Foung S.K. Hepatitis C virus E2 has three immunogenic domains containing conformational epitopes with distinct properties and biological functions. J. Virol. 78 17 (2004) 9224-9232
58. Koutsoudakis, G. et al. (personal communication).
59. Kuhn R.J., Zhang W., Rossmann M.G., Pletnev S.V., Corver J., Lenches E., Jones C.T., Mukhopadhyay S., Chipman P.R., Strauss E.G., Baker T.S., and Strauss J.H. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108 5 (2002) 717-725
60. Lagging L.M., Meyer K., Owens R.J., and Ray R. Functional role of hepatitis C virus chimeric glycoproteins in the infectivity of pseudotyped virus. J. Virol. 72 5 (1998) 3539-3546
61. Lanford R.E., and Bigger C. Advances in model systems for hepatitis C virus research. Virology 293 1 (2002) 1-9
62. Lavillette D., Morice Y., Germanidis G., Donot P., Soulier A., Pagkalos E., Sakellariou G., Intrator L., Bartosch B., Pawlotsky J.M., and Cosset F.L. Human serum facilitates hepatitis C virus infection, and neutralizing responses inversely correlate with viral replication kinetics at the acute phase of hepatitis C virus infection. J. Virol. 79 10 (2005) 6023-6034
63. Lavillette D., Tarr A.W., Voisset C., Donot P., Bartosch B., Bain C., Patel A.H., Dubuisson J., Ball J.K., and Cosset F.L. Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus. Hepatology 41 2 (2005) 265-274
64. Lechmann M., Murata K., Satoi J., Vergalla J., Baumert T.F., and Liang T.J. Hepatitis C virus-like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology 34 2 (2001) 417-423
65. Lescar J., Roussel A., Wien M.W., Navaza J., Fuller S.D., Wengler G., Wengler G., and Rey F.A. The fusion glycoprotein shell of Semliki Forest virus: an icosahedral assembly primed for fusogenic activation at endosomal pH. Cell 105 1 (2001) 137-148
66. Lindenbach B.D., and Rice C.M. Fields Virology 1 (2001) 991-1041
67. Lindenbach B.D., Evans M.J., Syder A.J., Wolk B., Tellinghuisen T.L., Liu C.C., Maruyama T., Hynes R.O., Burton D.R., McKeating J.A., and Rice C.M. Complete replication of hepatitis C virus in cell culture. Science (2005) 573-574
68. Liu B., and Krieger M. Highly purified scavenger receptor class B, type I reconstituted into phosphatidylcholine/cholesterol liposomes mediates high affinity high density lipoprotein binding and selective lipid uptake. J. Biol. Chem. 277 37 (2002) 34125-34135
69. Logvinoff C., Major M.E., Oldach D., Heyward S., Talal A., Balfe P., Feinstone S.M., Alter H., Rice C.M., and McKeating J.A. Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc. Natl. Acad. Sci. U.S.A. 101 27 (2004) 10149-10154
70. Lozach P.Y., Lortat-Jacob H., de Lacroix de Lavalette A., Staropoli I., Foung S., Amara A., Houles C., Fieschi F., Schwartz O., Virelizier J.L., Arenzana-Seisdedos F., and Altmeyer R. DC-SIGN and L-SIGN are high affinity binding receptors for hepatitis C virus glycoprotein E2. J. Biol. Chem. 278 22 (2003) 20358-20366
71. Lozach P.Y., Amara A., Bartosch B., Virelizier J.L., Arenzana-Seisdedos F., Cosset F.L., and Altmeyer R. C-type lectins L-SIGN and DC-SIGN capture and transmit infectious hepatitis C virus pseudotype particles. J. Biol. Chem. 279 31 (2004) 32035-32045
72. Ludwig I.S., Lekkerkerker A.N., Depla E., Bosman F., Musters R.J., Depraetere S., van Kooyk Y., and Geijtenbeek T.B. Hepatitis C virus targets DC-SIGN and L-SIGN to escape lysosomal degradation. J. Virol. 78 15 (2004) 8322-8332
73. Maggi F., Giorgi M., Fornai C., Morrica A., Vatteroni M.L., Pistello M., Siciliano G., Nuccorini A., and Bendinelli M. Detection and quasispecies analysis of hepatitis C virus in the cerebrospinal fluid of infected patients. J. Neurovirol. 5 3 (1999) 319-323
74. Manzini P., Dusheiko G.M., Brown J.C., Khakoo S.I., and Owen J.S. Hepatitis C virus (HCV) tends to associate preferentially with high-density lipoproteins by standard ultracentrifugal fractionation of plasma from patients with chronic HCV infection. Hepatol. Res. 11 3 (1998) 158-165
75. Matsuura Y., Tani H., Suzuki K., Kimura-Someya T., Suzuki R., Aizaki H., Ishii K., Moriishi K., Robison C.S., Whitt M.A., and Miyamura T. Characterization of pseudotype VSV possessing HCV envelope proteins. Virology 286 2 (2001) 263-275
76. McKeating J.A., Zhang L.Q., Logvinoff C., Flint M., Zhang J., Yu J., Butera D., Ho D.D., Dustin L.B., Rice C.M., and Balfe P. Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner. J. Virol. 78 16 (2004) 8496-8505
77. Mercer D.F., Schiller D.E., Elliott J.F., Douglas D.N., Hao C., Rinfret A., Addison W.R., Fischer K.P., Churchill T.A., Lakey J.R., Tyrrell D.L., and Kneteman N.M. Hepatitis C virus replication in mice with chimeric human livers. Nat. Med. 7 8 (2001) 927-933
78. Meunier J.C., Engle R.E., Faulk K., Zhao M., Bartosch B., Alter H., Emerson S.U., Cosset F.L., Purcell R.H., and Bukh J. Evidence for cross-genotype neutralization of hepatitis C virus pseudo-particles and enhancement of infectivity by apolipoprotein C1. Proc. Natl. Acad. Sci. U.S.A. 102 12 (2005) 4560-4565
79. Meyer K., Basu A., and Ray R. Functional features of hepatitis C virus glycoproteins for pseudotype virus entry into mammalian cells. Virology 276 1 (2000) 214-226
80. Meyer K., Beyene A., Bowlin T.L., Basu A., and Ray R. Coexpression of hepatitis C virus E1 and E2 chimeric envelope glycoproteins displays separable ligand sensitivity and increases pseudotype infectious titer. J. Virol. 78 23 (2004) 12838-12847
81. Michalak J.P., Wychowski C., Choukhi A., Meunier J.C., Ung S., Rice C.M., and Dubuisson J. Characterization of truncated forms of hepatitis C virus glycoproteins. J. Gen. Virol. 78 Pt 9 (1997) 2299-2306
82. Monazahian M., Bohme I., Bonk S., Koch A., Scholz C., Grethe S., and Thomssen R. Low density lipoprotein receptor as a candidate receptor for hepatitis C virus. J. Med. Virol. 57 3 (1999) 223-229
83. Monazahian M., Kippenberger S., Muller A., Seitz H., Bohme I., Grethe S., and Thomssen R. Binding of human lipoproteins (low, very low, high density lipoproteins) to recombinant envelope proteins of hepatitis C virus. Med. Microbiol. Immunol. (Berl) 188 4 (2000) 177-184
84. Morsica G., Tambussi G., Sitia G., Novati R., Lazzarin A., Lopalco L., and Mukenge S. Replication of hepatitis C virus in B lymphocytes (CD19+). Blood 94 3 (1999) 1138-1139
85. Muller H.M., Pfaff E., Goeser T., Kallinowski B., Solbach C., and Theilmann L. Peripheral blood leukocytes serve as a possible extrahepatic site for hepatitis C virus replication. J. Gen. Virol. 74 Pt 4 (1993) 669-676
86. Muller H.M., Kallinowski B., Solbach C., Theilmann L., Goeser T., and Pfaff E. B-lymphocytes are predominantly involved in viral propagation of hepatitis C virus (HCV). Arch. Virol., Suppl. 9 (1994) 307-316
87. Op De Beeck A., Voisset C., Bartosch B., Ciczora Y., Cocquerel L., Keck Z., Foung S., Cosset F.L., and Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 78 6 (2004) 2994-3002
88. Owsianka A., Clayton R.F., Loomis-Price L.D., McKeating J.A., and Patel A.H. Functional analysis of hepatitis C virus E2 glycoproteins and virus-like particles reveals structural dissimilarities between different forms of E2. J. Gen. Virol. 82 Pt 8 (2001) 1877-1883
89. Owsianka A., Tarr A.W., Juttla V.S., Lavillette D., Bartosch B., Cosset F.L., Ball J.K., and Patel A.H. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J. Virol. 79 17 (2005) 11095-11104
90. Penin F., Dubuisson J., Rey F.A., Moradpour D., and Pawlotsky J.M. Structural biology of hepatitis C virus. Hepatology 39 1 (2004) 5-19
91. Petracca R., Falugi F., Galli G., Norais N., Rosa D., Campagnoli S., Burgio V., Di Stasio E., Giardina B., Houghton M., Abrignani S., and Grandi G. Structure-function analysis of hepatitis C virus envelope-CD81 binding. J. Virol. 74 10 (2000) 4824-4830
92. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., and Abrignani S. Binding of hepatitis C virus to CD81. Science 282 5390 (1998) 938-941
93. Pohlmann S., Zhang J., Baribaud F., Chen Z., Leslie G.J., Lin G., Granelli-Piperno A., Doms R.W., Rice C.M., and McKeating J.A. Hepatitis C virus glycoproteins interact with DC-SIGN and DC-SIGNR. J. Virol. 77 7 (2003) 4070-4080
94. Pumeechockchai W., Bevitt D., Agarwal K., Petropoulou T., Langer B.C., Belohradsky B., Bassendine M.F., and Toms G.L. Hepatitis C virus particles of different density in the blood of chronically infected immunocompetent and immunodeficient patients: implications for virus clearance by antibody. J. Med. Virol. 68 3 (2002) 335-342
95. Qiao M., Murata K., Davis A.R., Jeong S.H., and Liang T.J. Hepatitis C virus-like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology 37 1 (2003) 52-59
96. Radkowski M., Wilkinson J., Nowicki M., Adair D., Vargas H., Ingui C., Rakela J., and Laskus T. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J. Virol. 76 2 (2002) 600-608
97. Rey F.A., Heinz F.X., Mandl C., Kunz C., and Harrison S.C. The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature 375 6529 (1995) 291-298
98. Roccasecca R., Ansuini H., Vitelli A., Meola A., Scarselli E., Acali S., Pezzanera M., Ercole B.B., McKeating J., Yagnik A., Lahm A., Tramontano A., Cortese R., and Nicosia A. Binding of the hepatitis C virus E2 glycoprotein to CD81 is strain specific and is modulated by a complex interplay between hypervariable regions 1 and 2. J. Virol. 77 3 (2003) 1856-1867
99. Roingeard P., Hourioux C., Blanchard E., Brand D., and Ait-Goughoulte M. Hepatitis C virus ultrastructure and morphogenesis. Biol. Cell 96 2 (2004) 103-108
100. Rumin S., Berthillon P., Tanaka E., Kiyosawa K., Trabaud M.A., Bizollon T., Gouillat C., Gripon P., Guguen-Guillouzo C., Inchauspe G., and Trepo C. Dynamic analysis of hepatitis C virus replication and quasispecies selection in long-term cultures of adult human hepatocytes infected in vitro. J. Gen. Virol. 80 Pt 11 (1999) 3007-3018
101. Sandrin V., Boulanger P., Penin F., Granier C., Cosset F.L., and Bartosch B. Assembly of functional hepatitis C virus glycoproteins on infectious pseudoparticles occurs intracellularly and requires concomitant incorporation of E1 and E2 glycoproteins. J. Gen. Virol. 86 Pt 12 (2005) 3189-3199
102. Saunier B., Triyatni M., Ulianich L., Maruvada P., Yen P., and Kohn L.D. Role of the asialoglycoprotein receptor in binding and entry of hepatitis C virus structural proteins in cultured human hepatocytes. J. Virol. 77 1 (2003) 546-559
103. Scarselli E., Ansuini H., Cerino R., Roccasecca R., Acali S., Filocamo G., Traboni C., Nicosia A., Cortese R., and Vitelli A. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus. EMBO J. 21 (2002) 5017-5025
104. Sherer N.M., Lehmann M.J., Jimenez-Soto L.F., Ingmundson A., Horner S.M., Cicchetti G., Allen P.G., Pypaert M., Cunningham J.M., and Mothes W. Visualization of retroviral replication in living cells reveals budding into multivesicular bodies. Traffic 4 11 (2003) 785-801
105. Silver D., Wang N., Xiao X., and Tall A. High density lipoprotein (HDL) particle uptake mediated by scavenger receptor class B type 1 results in selective sorting of HDL cholesterol from protein and polarized cholesterol secretion. J. Biol. Chem. 276 (2001) 25287-25293
106. Steinmann D., Barth H., Gissler B., Schurmann P., Adah M.I., Gerlach J.T., Pape G.R., Depla E., Jacobs D., Maertens G., Patel A.H., Inchauspe G., Liang T.J., Blum H.E., and Baumert T.F. Inhibition of hepatitis C virus-like particle binding to target cells by antiviral antibodies in acute and chronic hepatitis C. J. Virol. 78 17 (2004) 9030-9040
107. Stiasny K., Allison S.L., Marchler-Bauer A., Kunz C., and Heinz F.X. Structural requirements for low-pH-induced rearrangements in the envelope glycoprotein of tick-borne encephalitis virus. J. Virol. 70 11 (1996) 8142-8147
108. Stockert R.J. The asialoglycoprotein receptor: relationships between structure, function, and expression. Physiol. Rev. 75 3 (1995) 591-609
109. Takada A., Feldmann H., Ksiazek T.G., and Kawaoka Y. Antibody-dependent enhancement of Ebola virus infection. J. Virol. 77 13 (2003) 7539-7544
110. Takikawa S., Ishii K., Aizaki H., Suzuki T., Asakura H., Matsuura Y., and Miyamura T. Cell fusion activity of hepatitis C virus envelope proteins. J. Virol. 74 11 (2000) 5066-5074
111. Tassaneetrithep B., Burgess T.H., Granelli-Piperno A., Trumpfheller C., Finke J., Sun W., Eller M.A., Pattanapanyasat K., Sarasombath S., Birx D.L., Steinman R.M., Schlesinger S., and Marovich M.A. DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J. Exp. Med. 197 7 (2003) 823-829
112. Thomssen R., Bonk S., Propfe C., Heermann K.H., Kochel H.G., and Uy A. Association of hepatitis C virus in human sera with beta-lipoprotein. Med. Microbiol. Immunol. (Berl) 181 5 (1992) 293-300
113. Triyatni M., Saunier B., Maruvada P., Davis A.R., Ulianich L., Heller T., Patel A., Kohn L.D., and Liang T.J. Interaction of hepatitis C virus-like particles and cells: a model system for studying viral binding and entry. J. Virol. 76 18 (2002) 9335-9344
114. Triyatni M., Vergalla J., Davis A.R., Hadlock K.G., Foung S.K., and Liang T.J. Structural features of envelope proteins on hepatitis C virus-like particles as determined by anti-envelope monoclonal antibodies and CD81 binding. Virology 298 1 (2002) 124-132
115. Voisset C., Callens N., Blanchard E., Op De Beeck A., Dubuisson J., and Vu-Dac N. High density lipoproteins facilitate hepatitis C virus entry through the scavenger receptor class B type I. J. Biol. Chem. 280 9 (2005) 7793-7799
116. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Krausslich H.G., Mizokami M., Bartenschlager R., and Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. (2005) 791-796
117. Wellnitz S., Klumpp B., Barth H., Ito S., Depla E., Dubuisson J., Blum H.E., and Baumert T.F. Binding of hepatitis C virus-like particles derived from infectious clone H77C to defined human cell lines. J. Virol. 76 3 (2002) 1181-1193
118. Wunschmann S., Medh J.D., Klinzmann D., Schmidt W.N., and Stapleton J.T. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J. Virol. 74 21 (2000) 10055-10062
119. Xiang J., Wunschmann S., George S.L., Klinzman D., Schmidt W.N., LaBrecque D.R., and Stapleton J.T. Recombinant hepatitis C virus-like particles expressed by baculovirus: utility in cell-binding and antibody detection assays. J. Med. Virol. 68 4 (2002) 537-543
120. Yagnik A.T., Lahm A., Meola A., Roccasecca R.M., Ercole B.B., Nicosia A., and Tramontano A. A model for the hepatitis C virus envelope glycoprotein E2. Proteins 40 3 (2000) 355-366
121. Yamada E., Montoya M., Schuettler C.G., Hickling T.P., Tarr A.W., Vitelli A., Dubuisson J., Patel A.H., Ball J.K., and Borrow P. Analysis of the binding of hepatitis C virus genotype 1a and 1b E2 glycoproteins to peripheral blood mononuclear cell subsets. J. Gen. Virol. 86 Pt 9 (2005) 2507-2512
122. Zhang J., Randall G., Higginbottom A., Monk P., Rice C.M., and McKeating J.A. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 78 3 (2004) 1448-1455
123. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., and Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. (2005) 9294-9299